sulpiride

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Dose	Unit	Route
0.80	g	O
0.80	g	P

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2.28 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	70 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	133.89 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	27 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.94 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	6.50 hours	Lombardo F, Berellini G, Obach RS

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,TEK	24
kinase-selectivity-class	EIF2AK3,GRK2,PDK1,SIK2,TEK	5
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	1.476		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
rat-kpuu-brain	Rat brain Kpuu	0.012	%	High	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	145.01	24.33	71	4419	72385	90551572
Suicide attempt	116.29	24.33	62	4428	75337	90548620
Torsade de pointes	115.90	24.33	39	4451	15143	90608814
Parkinsonism	87.45	24.33	31	4459	14034	90609923
Drug interaction	71.85	24.33	78	4412	276375	90347582
Hypokalaemia	71.41	24.33	56	4434	131060	90492897
Toxicity to various agents	67.55	24.33	77	4413	287769	90336188
Ventricular fibrillation	65.30	24.33	25	4465	14019	90609938
Cerebellar syndrome	63.97	24.33	18	4472	3854	90620103
Somnolence	59.60	24.33	62	4428	209022	90414935
Serotonin syndrome	57.91	24.33	31	4459	37856	90586101
Fall	57.89	24.33	93	4397	481717	90142240
Hypomagnesaemia	56.88	24.33	30	4460	35558	90588399
Altered state of consciousness	54.45	24.33	28	4462	31504	90592453
Rhabdomyolysis	49.19	24.33	31	4459	51225	90572732
Drug abuse	48.78	24.33	37	4453	82310	90541647
Extrapyramidal disorder	48.27	24.33	21	4469	16282	90607675
Fracture	48.20	24.33	23	4467	22053	90601904
Psychomotor retardation	47.46	24.33	15	4475	4774	90619183
Intentional overdose	46.61	24.33	38	4452	93796	90530161
Hyponatraemia	40.54	24.33	41	4449	133497	90490460
Cardio-respiratory arrest	38.78	24.33	29	4461	63111	90560846
Product monitoring error	35.95	24.33	12	4478	4532	90619425
Tension	34.29	24.33	11	4479	3671	90620286
Long QT syndrome	33.29	24.33	11	4479	4026	90619931
Metabolic syndrome	32.23	24.33	9	4481	1873	90622084
Infectious mononucleosis	31.60	24.33	9	4481	2012	90621945
Persecutory delusion	31.59	24.33	10	4480	3198	90620759
Enuresis	30.98	24.33	10	4480	3404	90620553
Loss of consciousness	30.27	24.33	36	4454	140202	90483755
Syncope	30.20	24.33	35	4455	132628	90491329
Hyperthermia	29.58	24.33	13	4477	10322	90613635
Dystonia	29.21	24.33	15	4475	16804	90607153
Hepatic function abnormal	25.64	24.33	20	4470	46268	90577689
Social anxiety disorder	25.56	24.33	6	4484	627	90623330
Blood lactic acid increased	24.98	24.33	11	4479	8767	90615190
Salivary hypersecretion	24.61	24.33	11	4479	9081	90614876

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicide attempt	77.38	24.68	43	2558	46057	42572677
Ketoacidosis	58.60	24.68	19	2582	5333	42613401
Extrapyramidal disorder	56.55	24.68	25	2576	16387	42602347
Neuroleptic malignant syndrome	53.11	24.68	26	2575	21446	42597288
Schizophrenia	52.91	24.68	21	2580	10529	42608205
Reduced facial expression	51.27	24.68	13	2588	1520	42617214
Dissociative disorder	50.57	24.68	11	2590	661	42618073
Mental impairment	46.45	24.68	20	2581	12297	42606437
Mean cell haemoglobin concentration decreased	36.72	24.68	10	2591	1540	42617194
Parkinsonism	35.99	24.68	16	2585	10607	42608127
Disturbance in attention	34.70	24.68	22	2579	29844	42588890
Panic attack	32.25	24.68	15	2586	11030	42607704
Dissociation	31.71	24.68	11	2590	3787	42614947
Depressed mood	29.11	24.68	18	2583	23366	42595368
Pneumonia aspiration	28.60	24.68	24	2577	50054	42568680
Eosinophil count decreased	28.49	24.68	10	2591	3566	42615168
Thinking abnormal	28.22	24.68	12	2589	7149	42611585
Bradyphrenia	28.22	24.68	11	2590	5251	42613483
Mental disorder	27.98	24.68	16	2585	18013	42600721
Cognitive disorder	27.36	24.68	20	2581	34152	42584582
Fear	26.27	24.68	13	2588	10952	42607782
Toxicity to various agents	25.41	24.68	48	2553	229088	42389646
Suicidal ideation	25.29	24.68	22	2579	48139	42570595
Product prescribing error	24.88	24.68	17	2584	26095	42592639

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

sulpiride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicide attempt	151.62	22.42	90	7022	103304	110478883
Electrocardiogram QT prolonged	149.82	22.42	91	7021	108869	110473318
Parkinsonism	118.82	22.42	47	7065	22140	110560047
Torsade de pointes	94.16	22.42	40	7072	22560	110559627
Extrapyramidal disorder	94.11	22.42	43	7069	28824	110553363
Neuroleptic malignant syndrome	69.87	22.42	37	7075	34022	110548165
Toxicity to various agents	68.85	22.42	116	6996	480439	110101748
Psychomotor retardation	61.74	22.42	22	7090	7770	110574417
Fall	59.36	22.42	124	6988	603358	109978829
Cerebellar syndrome	58.41	22.42	20	7092	6282	110575905
Altered state of consciousness	56.59	22.42	39	7073	57587	110524600
Somnolence	55.30	22.42	81	7031	297368	110284819
Hypokalaemia	54.80	22.42	63	7049	182385	110399802
Mental impairment	53.35	22.42	27	7085	22612	110559575
Serotonin syndrome	48.79	22.42	36	7076	59117	110523070
Dissociative disorder	48.15	22.42	12	7100	1239	110580948
Rhabdomyolysis	47.43	22.42	48	7064	120353	110461834
Ketoacidosis	45.84	22.42	19	7093	10068	110572119
Drug abuse	44.64	22.42	56	7056	177355	110404832
Cognitive disorder	44.16	22.42	40	7072	87471	110494716
Intentional overdose	43.61	22.42	48	7064	132453	110449734
Product prescribing error	41.79	22.42	31	7081	51300	110530887
Hypomagnesaemia	41.56	22.42	33	7079	60337	110521850
Drug interaction	41.42	22.42	96	7016	500087	110082100
Depressed mood	41.35	22.42	33	7079	60776	110521411
Fracture	40.02	22.42	23	7089	24765	110557422
Schizophrenia	39.98	22.42	22	7090	21804	110560383
Hepatic function abnormal	39.62	22.42	38	7074	89257	110492930
Reduced facial expression	39.43	22.42	13	7099	3638	110578549
Tension	38.95	22.42	14	7098	5064	110577123
Ventricular fibrillation	33.74	22.42	25	7087	41288	110540899
Disturbance in attention	30.61	22.42	28	7084	61967	110520220
Panic attack	29.38	22.42	20	7092	28920	110553267
Hyponatraemia	29.04	22.42	51	7061	217602	110364585
Mental disorder	28.41	22.42	22	7090	38769	110543418
Pneumonia aspiration	27.71	22.42	30	7082	81203	110500984
Overdose	27.66	22.42	52	7060	233742	110348445
Hyperthermia	27.22	22.42	17	7095	21255	110560932
Cardio-respiratory arrest	26.66	22.42	35	7077	115801	110466386
Dystonia	26.59	22.42	18	7094	25787	110556400
Fear	25.88	22.42	17	7095	23176	110559011
Suicidal ideation	25.78	22.42	31	7081	93906	110488281
Product monitoring error	25.06	22.42	12	7100	8915	110573272
Bradyphrenia	24.78	22.42	13	7099	11715	110570472
Atopic keratoconjunctivitis	24.59	22.42	4	7108	45	110582142
Long QT syndrome	24.44	22.42	11	7101	7107	110575080
Anxiety	24.00	22.42	62	7050	345016	110237171
Mean cell haemoglobin concentration decreased	23.47	22.42	10	7102	5672	110576515
Enuresis	23.05	22.42	9	7103	4087	110578100
Eosinophil count decreased	22.91	22.42	10	7102	6008	110576179
Neutrophil count decreased	22.52	22.42	33	7079	120908	110461279

Source	Code	Description
ATC	N05AL01	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Benzamides
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D018687	Antidepressive Agents, Second-Generation
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35474	anxiolytic drug
CHEBI has role	CHEBI:35476	antipsychotic agent
CHEBI has role	CHEBI:48561	dopaminergic antagonist
CHEBI has role	CHEBI:50919	antiemetic

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.12	CHEMBL	IUPHAR
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.12	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	8.10	CHEMBL
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	5.68	CHEMBL
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		IC50	7.40	WOMBAT-PK
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	5.92	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	7.51	CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN		Ki	8.41	CHEMBL
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	6.76	CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	7.74	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	8.44	CHEMBL
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	4.97	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	9.10	CHEMBL
Carbonic anhydrase	Enzyme		CYNT_HELPY		Ki	6.75	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Kd	8.82	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_CANFA		IC50	6.70	CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE		Ki	7.14	CHEMBL
Carbonic anhydrase	Enzyme		CAN_YEAST		Ki	6.91	CHEMBL
Carbonic anhydrase	Enzyme		CAN_CANAL		Ki	7.40	CHEMBL
Carbonic anhydrase	Enzyme		Q6FTL6_CANGA		Ki	6.95	CHEMBL
Alpha carbonic anhydrase	Enzyme		B5SU02_9CNID		Ki	6.37	CHEMBL
Carbonic anhydrase	Enzyme		C0IX24_9CNID		Ki	6.38	CHEMBL
Carbonic anhydrase 2	Enzyme		Q3I4V7_CRYNV		Ki	6.09	CHEMBL
Astrosclerin-3	Enzyme		A6YCJ1_9METZ		Ki	6.42	CHEMBL
Beta-carbonic anhydrase 1	Enzyme		MTCA1_MYCTU		Ki	5.64	CHEMBL
Delta carbonic anhydrase	Enzyme		Q5U9J1_THAWE		Ki	6.59	CHEMBL
Carbonic anhydrase 2	Enzyme		MTCA2_MYCTU		Ki	6.58	CHEMBL
Dopamine receptor	GPCR		DRD1_RAT DRD3_RAT DRD5_RAT DRD4_RAT DRD2_RAT		Ki	5.80	CHEMBL
Carbonic anhydrase	Enzyme		Q5TU56_ANOGA		Ki	7.53	CHEMBL
Carbonic anhydrase, alpha family	Enzyme		Q31FD6_HYDCU		Ki	6.06	CHEMBL
Carbonate dehydratase	Enzyme		B2V8E3_SULSY		Ki	7.17	CHEMBL

ID	Source
N0000166882	NUI
D01226	KEGG_DRUG
C0038803	UMLSCUI
CHEBI:32168	CHEBI
CHEMBL26	ChEMBL_ID
DB00391	DRUGBANK_ID
D013469	MESH_DESCRIPTOR_UI
5355	PUBCHEM_CID
5501	IUPHAR_LIGAND_ID
2359	INN_ID
7MNE9M8287	UNII
10239	RXNORM
003764	NDDF
321506004	SNOMEDCT_US
395891007	SNOMEDCT_US
7MNE9M8287	INXIGHT DRUGS

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.47	acidic
pKa2	12.66	acidic
pKa3	8.85	Basic